- PharmAust (PAA) has officially started recruiting patients for a second-phase clinical trial testing one of its key drugs against cancer in dogs
- The phase IIb trial will test PharmAust’s monepantel (MPL) treatment against naive B-cell lymphoma in dogs
- This is one of the most common types of cancer in dogs, accounting for around 20 per cent of all canine cancers
- PharmAust has started treating eligible dogs with MPL under the trial and also started giving six dogs not eligible for the trial compassionate treatment
- The company says the overall market for veterinary medicinal products is more than $22 billion
- Shares in PharmAust closed grey this afternoon at 10 cents each
